These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 10476930)

  • 21. Autoantibodies to cardiac myosin in mouse cytomegalovirus myocarditis.
    O'Donoghue HL; Lawson CM; Reed WD
    Immunology; 1990 Sep; 71(1):20-8. PubMed ID: 2170269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of RNA interference and virus receptor trap exerts additive antiviral activity in coxsackievirus B3-induced myocarditis in mice.
    Stein EA; Pinkert S; Becher PM; Geisler A; Zeichhardt H; Klopfleisch R; Poller W; Tschöpe C; Lassner D; Fechner H; Kurreck J
    J Infect Dis; 2015 Feb; 211(4):613-22. PubMed ID: 25193982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. QiHong prevents death in coxsackievirus B3 induced murine myocarditis through inhibition of virus attachment and penetration.
    Song X; Liu Z; Wang H; Xin Y; Wang X; Chen J; Shi Y; Zhang C; Hui R
    Exp Biol Med (Maywood); 2007 Dec; 232(11):1441-8. PubMed ID: 18040068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bifidobacterium as an oral delivery carrier of interleukin-12 for the treatment of Coxsackie virus B3-induced myocarditis in the Balb/c mice.
    Yu Z; Huang Z; Sao C; Huang Y; Zhang F; Yang J; Lian J; Zeng Z; Luo W; Zeng W; Deng Q
    Int Immunopharmacol; 2012 Jan; 12(1):125-30. PubMed ID: 22088614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effects of immunoglobulin on murine myocarditis caused by influenza A virus: experimental study].
    Kishimoto C; Hiraoka Y; Takada H; Kurokawa M; Ochiai H
    J Cardiol; 2005 Jun; 45(6):247-55. PubMed ID: 15991608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokine profiles in heart, spleen, and thymus during the acute stage of experimental coxsackievirus B3-induced chronic myocarditis.
    Schmidtke M; Glück B; Merkle I; Hofmann P; Stelzner A; Gemsa D
    J Med Virol; 2000 Aug; 61(4):518-26. PubMed ID: 10897072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral administration of IFN-alpha is superior to subcutaneous administration of IFN-alpha in the suppression of chronic relapsing experimental autoimmune encephalomyelitis.
    Brod SA; Khan M
    J Autoimmun; 1996 Feb; 9(1):11-20. PubMed ID: 8845048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of pravastatin on myocardial connexin 43, IFN-gamma and IL-10 expressions in a murine model of viral myocarditis induced by Coxsackievirus B3].
    Wu SY; Fang HY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Jan; 36(1):72-6. PubMed ID: 19099934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity.
    Neyts J; De Clercq E
    Verh K Acad Geneeskd Belg; 1994; 56(6):561-92. PubMed ID: 7892749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective effects of 20(s)-protopanaxtriol on viral myocarditis infected by coxsackievirus B3.
    Wang X; Wang Y; Ren Z; Qian C; Li Y; Wang Q; Zhang Y; Zheng L; Jiang J; Yang C; Wang D; Zhang Y; Fan J; Wang Y
    Pathobiology; 2012; 79(6):285-9. PubMed ID: 22688124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose orally administered type I interferon reduces splenic B cell numbers in mice.
    Bosio E; Cluning CL; Beilharz MW
    J Interferon Cytokine Res; 2001 Sep; 21(9):721-8. PubMed ID: 11576466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lessons from animal experiments in myocarditis.
    Matsumori A
    Herz; 1992 Apr; 17(2):107-11. PubMed ID: 1349548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon subtype gene therapy for regulating cytomegalovirus disease.
    James CM; Bartlett EJ; Mansfield JP; Cull VS
    Methods Mol Med; 2005; 116():207-19. PubMed ID: 16000864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of interferon induction in mice of resistant and susceptible strains during murine cytomegalovirus infection.
    Allan JE; Shellam GR
    J Gen Virol; 1985 May; 66 ( Pt 5)():1105-12. PubMed ID: 2582082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunomodulation of murine cytomegalovirus-induced myocarditis in mice treated with lipopolysaccharide and tumor necrosis factor.
    Lenzo JC; Fairweather D; Shellam GR; Lawson CM
    Cell Immunol; 2001 Oct; 213(1):52-61. PubMed ID: 11747356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Seven days of low-dose orally administered murine type I interferon does not cause priming in vivo.
    Bosio E; Beilharz MW
    J Interferon Cytokine Res; 2001 Jul; 21(7):463-7. PubMed ID: 11506738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of extrahepatic biliary atresia with interferon-alpha in a murine infectious model.
    Petersen C; Bruns E; Kuske M; von Wussow P
    Pediatr Res; 1997 Nov; 42(5):623-8. PubMed ID: 9357935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pivotal role of animal models in the development of new therapies for cytomegalovirus infections.
    Kern ER
    Antiviral Res; 2006 Sep; 71(2-3):164-71. PubMed ID: 16828175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of free immunoglobulin light chains on viral myocarditis.
    Matsumori A; Shimada M; Jie X; Higuchi H; Groot Kormelink T; Redegeld FA
    Circ Res; 2010 May; 106(9):1533-40. PubMed ID: 20360247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mouse cytomegalovirus infection induces antibodies which cross-react with virus and cardiac myosin: a model for the study of molecular mimicry in the pathogenesis of viral myocarditis.
    Lawson CM; O'Donoghue HL; Reed WD
    Immunology; 1992 Mar; 75(3):513-9. PubMed ID: 1315309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.